Monitor Nasdaq delisting risk closely as company is below minimum equity requirement. Despite recent insider buying, the dilutive financing and delisting threat suggest significant financial distress. Watch for future capital raises or restructuring announcements.
Price Chart
Executive Summary
Vivos Therapeutics raised $2.39 million through a private placement with existing backer V-Co Investors 3 LLC, converting $1.4 million of bridge debt and adding $850,000 in new cash. The deal includes immediate warrants and pre-funded shares, but the company disclosed it is below Nasdaq's minimum equity requirement and faces potential delisting.
Key Financial Metrics
Key Facts
- Raised $2.39 million through private placement with V-Co Investors 3 LLC
- $1.4 million from conversion of prior bridge loan, $850,000 in new cash
- Issued 1,353,625 shares at $1.34 per share and pre-funded warrants for 429,957 shares
- Granted immediate exercisable warrants for 3,567,164 shares at $1.09 per share (2-year and 5-year terms)
- Company disclosed stockholders' equity below Nasdaq's $2.5 million minimum, facing potential delisting
- Recent insider buying totals $6.8 million over 30 days
Financial Impact
Raised $2.39 million through equity issuance and debt conversion, with significant dilution from immediate warrants. Market cap of $14 million makes this a substantial capital raise.
Risk Factors
- Potential Nasdaq delisting due to insufficient stockholders' equity
- Significant shareholder dilution from immediate exercisable warrants
- Continued reliance on a single investor for funding
- Small market cap makes company vulnerable to liquidity issues
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-015132 |
| Exhibit: ex4-2.htm | 0001493152-26-015132 |
| Exhibit: ex4-3.htm | 0001493152-26-015132 |
| Exhibit: ex4-1.htm | 0001493152-26-015132 |
| Document: form8-k.htm | 0001493152-26-015132 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | 8-K | $0.1347 | awaiting T+60 | — | $0.1310 (−2.75%) |
Oct 19, 2026 8d ago | Press Release | $0.1410 | awaiting T+60 | — | $0.1310 (−7.09%) |
Oct 19, 2026 8d ago | 8-K | $0.1406 | awaiting T+60 | — | $0.1310 (−6.83%) |
Oct 15, 2026 12d ago | 8-K | $0.1428 | awaiting T+60 | — | $0.1310 (−8.26%) |
Oct 15, 2026 12d ago | Press Release | $0.1428 | awaiting T+60 | — | $0.1310 (−8.26%) |
Sep 30, 2026 26d ago | 8-K | $0.1490 | awaiting T+60 | — | $0.1310 (+12.08%) |
Aug 28, 2026 8w ago | Press Release | $0.2249 | awaiting T+60 | — | $0.1310 (−41.75%) |
Aug 21, 2026 9w ago | 8-K | $0.2768 | awaiting T+60 | — | $0.1310 (−52.67%) |
Aug 14, 2026 10w ago | Press Release | $0.3012 | awaiting T+60 | — | $0.1310 (+56.51%) |
Aug 14, 2026 10w ago | Press Release | $0.3433 | awaiting T+60 | — | $0.1310 (−61.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers